We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Coronado Biosciences Appoints Karin Hehenberger, M.D., Ph.D. as Senior Vice President of Scientific Affairs

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Coronado Biosciences Appoints Karin Hehenberger, M.D., Ph.D. as Senior Vice President of Scientific Affairs"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Dr. Bobby W. Sandage, Jr., Coronado’s President and CEO, said, “Karin joins Coronado with extensive industry experience and a unique background in healthcare, resulting from her work at pharmaceutical, biotechnology and not for profit companies, as well as in private equity and equity research. In this newly created role, Karin will focus on initiating investigator sponsored clinical trials with CNDO-201, our lead compound for the treatment of autoimmune diseases. She will also work with key opinion leaders and organizations to obtain funding and initiate additional studies in indications where CNDO-201 shows promise.” Most recently, Dr. Hehenberger was Senior Vice President for Strategic Alliances at the Juvenile Diabetes Research Foundation (JDRF). She was responsible for advancing the JDRF's involvement with scientific, financial, and commercial partners in the diabetes community. Prior to JDRF, Dr. Hehenberger worked at Johnson & Johnson as Vice President of Metabolic Strategy and Business Development.

Dr. Hehenberger holds M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden. She continued her research as a JDRF post-doctoral fellow at the Joslin Diabetes Center at Harvard Medical School and then moved into the business aspect of medicine, as a strategic management consultant at McKinsey & Co. Dr. Hehenberger also has experience in public and private equity, having been a partner in Scandinavian Life Science Venture, a buy-side healthcare equity analyst at Brummer & Partners and Argus Partners, and on the senior management team of Eyetech Pharmaceuticals.